BACKGROUND: Inflammation and oxidative stress are associated with atherosclerosis. Myeloperoxidase (MPO) is linked to both inflammation and oxidative stress by its location in leukocytes and its role in catalyzing the formation of oxidizing agents. Recent evidence suggests that MPO activity precipitates atherogenesis. Measurement of MPO in plasma may therefore contribute to cardiovascular disease (CVD) risk stratification.
used in routine clinical practice, however, standardization of sampling and laboratory procedures is needed.
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Cardiovascular disease (CVD) 3 is the leading cause of death in Western societies. CVD mortality and morbidity are promoted by major CVD risk factors, such as hyperlipidemia, hypertension, and smoking. The sequence of events leading to CVD includes endothelial dysfunction, atherosclerotic plaque formation, and rupture (1 ) . Inflammation has been implicated in all these stages in the evolution of atherosclerotic plaques (1 ) . Moreover, oxidative stress is currently considered a key event in CVD development (2 ) .
Myeloperoxidase (MPO) is an enzyme linked to both inflammation and oxidative stress. It is abundantly expressed in the azurophilic granules of most leukocyte subspecies, including neutrophils and monocytes (3 ) . MPO is released by leukocytes in a state of inflammation and catalyzes the formation of several reactive species, including hypochlorous acid, and thus has a role in host defense against microorganisms (3 ) . Paradoxically, MPO has been implicated in initiation and propagation of atherosclerosis. In the past few years, evidence emerging from epidemiological studies has shown that higher concentrations of MPO are associated with an increased CVD risk, independent of classical CVD risk factors (4 -15 ) . However, comparison of these epidemiological studies with regard to MPO and CVD outcome is hampered by the fact that various assay methods and sampling procedures have been applied. The differences that are attributable to the use of various methods may have important implications for the interpretation of the results of these studies.
This review presents epidemiological evidence for MPO as a relevant biomarker with respect to CVD outcome, reviews the pathophysiological mechanisms linking MPO to CVD, and addresses preanalytical and analytical issues in measurement of MPO.
Myeloperoxidase and Cardiovascular Disease: Epidemiological Studies
A number of epidemiological studies have been reported that address the association of MPO with CVD and markers of atherosclerosis in a wide range of patients populations, including patients with established atherosclerosis and patients with an acute presentation with chest pain (Table 1) .
ESTABLISHED ATHEROSCLEROSIS
The first epidemiological report assessing the association between MPO and CVD was a case-control study published by Zhang and coworkers in 2001 (15 ) . The authors studied the relation of MPO, expressed either as mass per milligram of neutrophil protein or as MPO mass per milliliter of blood, with coronary artery disease (CAD) risk in a case-control design with 158 patients with established CAD and 175 controls. CAD patients had significantly higher concentrations of MPO compared to the controls, and it was demonstrated by multivariate logistic regression analysis adjusted for traditional CVD risk factors that MPO was associated with an 11.9-fold (95% CI, 5.5-25.5, upper vs lower quartile) increased risk for CAD for leukocyte MPO, and a 20.4-fold (95% CI, 8.9 -47.7, upper vs lower quartile) increased risk for CAD for blood MPO. In a cross-sectional study by Duzguncinar et al., MPO was increased in patients with CAD and correlated to the extent and severity of atherosclerosis of the coronary vessels (16 ) . Meuwese and coworkers studied the association of MPO with CAD in 1138 patients with CAD and 2237 control s (11 ) . These investigators demonstrated that MPO (upper vs lower quartile) was related to CAD after adjustment for traditional risk factors [odds ratio (OR), 1.36 (95% CI, 1.07-1.73)]. In a case-control study in 680 patients, 382 patients with stable CAD and 194 controls with normal coronary angiograms, MPO was higher in patients with CAD compared to controls (14 ) . In addition, MPO concentrations were found to correlate with the presence of CAD [OR, 2.08 (95% CI, 1.54 -2.81)]. Mocatta and coworkers studied the 5-year all-cause mortality rate in 512 patients with established myocardial infarction (12 ) (9 ) . Patients with progressive stenosis had significantly higher baseline MPO concentrations compared to patients with stable disease. Interestingly, the relation between MPO and progression of stenosis was modified by HDL cholesterol level. An MPO concentration above the median was associated with a 2.6-fold increased risk (95% CI, 1.4 -4.8) of disease progression, but only in patients with HDL cholesterol concentrations below the median. Altogether, the results of these studies indicate that MPO may be a valuable novel marker for CVD events. However, one should keep in mind that publication bias due to unpublished negative findings cannot be ruled out. Stefanescu and coworkers found no independent association between MPO and all-cause mortality in 382 patients with stable CAD during 3.5 years of follow-up (17 ) . In contrast to the above-mentioned studies, all of which had reported significant associations between MPO and CVD, 1 case-control study in HIV patients showed no significant independent association of MPO with CVD events (18 ) . Another study, in patients undergoing elective coronary angiography, showed no significant differences in MPO concentrations for those with proven stable CAD compared to those without proven CAD (19 ) . A possible explanation for this negative finding might be the lower risk in stable vs unstable CAD. Indeed, cardiovascular events are thought to be more likely in unstable CVD (20 ) . These observations may thus indicate that MPO is a particularly useful biomarker in high-risk populations. . Another cross-sectional study showed that MPO had a higher diagnostic sensitivity and specificity in identifying patients with AMI than the total white blood cell count and 3-chlorotyrosine (24 ) . All in all, these studies indicate that measurement of MPO in patients presenting with acute chest pain provides clinically relevant information. It should be noted, however, that between-study differences in cutoff values for both MPO and the cardiac troponins might have affected the diagnostic and prognostic value of MPO compared to troponins.
MPO as a Causal Factor in the Pathogenesis of Atherosclerosis
MPO is important in host defense against pathogens. On the other hand, as discussed above, a considerable number of epidemiological and clinical studies have demonstrated an association between increased concentrations of MPO and CVD, independent of classical risk factors. The source of MPO in plasma is activated leukocytes. Release of MPO and subsequent formation of reactive species (MPO-derived reactive species) (3 ) may be triggered by several mechanisms. First, it is known that inflammation induces recruitment and activation of white blood cells. Second, minimally modified LDL particles in the intima may trigger the influx of monocytes that mature into resident macrophages, some of which express MPO. Third, neutrophils in the blood stream are attracted and bound to sites of damaged endothelium. MPO released by these adherent leukocytes is initially bound to the vascular endothelium and subsequently transcytosed to the subendothelial matrix (25 ) . Therefore, both local release by resident macrophages and transcytosis of intraluminally produced MPO are sources of MPO in the vascular wall.
The microenvironment of the subendothelial space is especially conducive to MPO activity. Mitochondrial respiration, NAD(P)H oxidases, xanthine oxidase, and uncoupled nitric oxide synthase (NOS) are major sources of the highly reactive superoxide radical, which is actively converted into hydrogen peroxide by superoxide dismutase. Although less reactive than the superoxide radical, hydrogen peroxide is the cosubstrate for all MPO-catalyzed reactions. MPO amplifies the oxidative potential of hydrogen peroxide by producing a variety of reactive oxidants, including chlorinating and nitrating species. In the following sections some targets of MPO-derived reactive substances are briefly described, but it should be noted that many more cellular macromolecules and processes are adversely affected by vascular MPO activity. Key features of the adverse role of MPO in the vascular wall are depicted in Fig. 1 .
LDL OXIDATION BY MPO
The oxidative modification of LDL is an early event in atherosclerosis, and oxidized LDL contributes to atherogenesis by promoting cholesterol deposition and transformation of macrophages into foam cells (2 ) . Retention of LDL in the subendothelial space makes LDL a major target for oxidation by prooxidants produced by arterial wall cells. Sources of oxidants include NAD(P)H oxidases, xanthine oxidase, lipoxygenases, mitochondrial respiration, uncoupled NOS, and MPO. MPO is a highly cationic protein and can bind to endothelial cells, leukocytes, and LDL. The association of MPO with LDL may enhance oxidation of this lipoprotein (26 ) . MPO generates a number of reactive species, including hypochlorous acid, chloramines, tyrosyl radicals, and nitrogen dioxide, that oxidize the protein, lipid, and antioxidant constituents of LDL (27 ) . Many of the primary oxidation products are unstable and serve as reactive intermediates that promote further oxidative modifications of LDL and may also lead to cross-linking and aggregation. However, a limited number of stable oxidation products have been identified that may serve as biomarkers of MPOcatalyzed oxidation. The modified tyrosine residues 3-nitrotyrosine and 3-chlorotyrosine are among the best characterized of these stable oxidation products (28 ) . Although MPO-generated reactive nitrogen species are involved in the conversion of tyrosine into 3-nitrotyrosine, other mechanisms may contribute to the formation of 3-nitrotyrosine as well. Notably, peroxynitrite, the reaction product of nitric oxide and superoxide, is also involved in the generation of 3-nitrotyrosine. In contrast to 3-nitrotyrosine, 3-chlorotyrosine is uniquely produced by MPO, and may therefore serve as a unique molecular fingerprint for MPO-catalyzed oxidation. Hazen and Heinecke reported that 3-chlorotyrosine was 6-fold higher in human advanced atherosclerotic lesions compared with normal aortic tissue. Moreover, the concentration of 3-chlorotyrosine in LDL isolated from atherosclerotic intima was 30-fold higher than in circulating LDL (29 ) . Mocatta et al. (12 ) measured chlorotyrosine in total plasma protein, however, and found no differences between groups that varied by 5-fold in mean MPO con- LDL particles penetrating the arterial intima may be minimally modified (mmLDL) by reactive oxygen species (ROS). Subsequently, mmLDL induces monocytes to migrate into the vascular wall, where they differentiate into macrophages. Oxidized LDL (oxLDL) is recognized by scavenger receptors of macrophages, and excess uptake leads to foam cell formation. MPO is released by macrophages in a state of inflammation and catalyzes the formation of myeloperoxidase-derived reactive species (MDRS) using chloride, thiocyanate, or NO as substrate and hydrogen peroxide as cosubstrate. Scavenging of NO may result in impaired vasodilation. Moreover, MDRS may promote atherosclerosis in different ways as indicated by the blue arrows. MDRS may oxidize LDL particles more extensively, forming oxidized LDL (oxLDL), and render HDL dysfunctional by promoting formation of oxidized HDL (oxHDL), thereby impairing HDL's protective effect on LDL particles and inhibiting reverse-cholesterol transport. MDRS may also destabilize plaques by weakening the fibrous cap.
centration or by 20-fold in protein carbonyls. From these results they concluded that any hypochlorous acid generated by MPO in plasma is insufficient to be the source of protein carbonyls. Although 3-chlorotyrosine constitutes but a minor fraction of oxidation products in LDL, it carries a very specific MPO signature. Recently it has been shown that thiocyanate, which is abundantly present in plasma and is increased in smokers, is oxidized by MPO to cyanate that may, through carbamylation of proteins, alter their structure and function (30 ) . This study clearly showed that MPO-catalyzed carbamylation might enhance the proatherogenic properties of LDL.
Taken together, these data strongly suggest that MPO is implicated in oxidative modification of LDL in the vascular intima, resulting in conversion of LDL into an atherogenic form.
IMPAIRMENT OF HDL FUNCTION BY MPO
In addition to playing a central role in cholesterol efflux and reverse-cholesterol transport, HDL also possesses antiinflammatory and antioxidative properties (31 ) . Although the exact mechanisms are not fully understood, some of the apolipoproteins and enzymes associated with HDL particles have antioxidative capacities. In this respect the protective role of HDL in MPO-mediated LDL oxidation is important. Mechanisms by which HDL can prevent or delay oxidation in the vessel wall include binding of transition metal ions and removal of oxidized (phospho)lipids and shortchain aldehydes from cells and LDL. After uptake by HDL, these oxidation products are either hydrolyzed by HDL-associated enzymes, such as plateletactivating factor acetylhydrolase and paraoxonase, or remain associated with HDL and are eventually eliminated from the circulation after hepatic uptake of HDL. The antiinflammatory activity of HDL is probably closely linked to its antioxidative activity, because many oxidized lipids possess potent proinflammatory properties and can trigger arterial inflammation. HDL particles decrease expression of adhesion molecules on endothelial cells and inhibit adhesion of monocytes to these cells and entry of inflammatory cells into the intima.
In metabolic diseases associated with accelerated atherosclerosis, HDL particles may become functionally defective (31 ) . Dysfunctional HDL particles lack atheroprotective properties and promote proinflammatory effects. Over the past few years it has become clear that MPO is involved in rendering HDL dysfunctional (32) (33) (34) . Apolipoprotein A-I (apoA-I) is a preferred target for MPO-catalyzed oxidation, as evidenced by an approximately 100-fold enrichment of both 3-nitrotyrosine and 3-chlorotyrosine in apoA-I recovered from circulatory HDL compared to other proteins in the circulation (35 ) . Moreover, enrichment of these oxidative modifications in apoA-I isolated from human atherosclerotic plaques was even higher. A higher 3-nitrotyrosine and 3-chlorotyrosine content of HDL was significantly associated with diminished cholesterol efflux capacity (35, 36 ) . A strong association between apoA-I modification and the prevalence of CVD has been observed. Individuals with an apoA-I 3-chlorotyrosine content in the highest tertile were 16-fold more likely to have CVD compared to those with apoA-I 3-chlorotyrosine in the lowest tertile (35 ) . Selective targeting of apoA-I is explained by the fact that apoA-I contains a specific binding site for MPO (35, 36 ) . Importantly, HDL-bound MPO retains its enzymatic activity, and binding to HDL may protect MPO from cellular uptake and degradation. Interestingly, MPO-dependent modification of HDL markedly increases the binding affinity of HDL for MPO, which has been proposed to lead to a vicious cycle of MPOdependent modifications at sites of chronic inflammation (37 ) . It should be noted that nitrotyrosine and chlorotyrosine in particular serve as molecular fingerprints for involvement of MPO in oxidative modification of HDL, but most likely other MPO-catalyzed modifications are quantitatively more important in generating dysfunctional HDL.
MPO REDUCES THE BIOAVAILABILITY OF NITRIC OXIDE
NO produced by endothelial NOS is a powerful vasodilator and as such plays a critical role in the regulation of vascular tone. Additionally, NO suppresses binding of circulating cells to the endothelium and inhibits proliferation of smooth muscle cells in the vascular wall (Fig. 1) . Taken together, these findings indicate that NO is a critical element in vascular homeostasis, and consequently insufficient production and/or increased scavenging of NO may impair vascular function and accelerate atherosclerosis. There are strong indications that MPO, by several mechanisms, may reduce the bioavailability of NO. First, NO serves as a substrate for peroxidases and MPO may thus serve as a catalytic sink for NO (38 ) . Second, scavenging of NO by MPOderived reactive substances may further reduce the bioavailability of NO. Third, hypochlorous acid can react with nitrogen atoms of the NOS substrate arginine to produce chlorinated arginine species that are inhibitors of all isoforms of NOS and have been shown to impair endothelium-dependent relaxation of rat aortic rings (39 ) . Finally, it has been demonstrated that hypochlorous acid is a potent inducer of uncoupling of endothelial NOS, thereby turning NOS into a superoxide-producing enzyme (40 ) . Although the relative impact of these mechanisms is currently unknown, it is clear that MPO, by catalytic as well as noncatalytic processes, depletes NO in the vascular wall. In agreement with this notion was the observation, in hu-man study participants, of a strong inverse association between MPO serum concentrations and brachial artery flow-mediated dilation, which remained significant after adjustment for classic CVD risk factors and CRP (41 ) . In a study by Baldus et al., release of vascular MPO from the subendothelial space by intravenous administration of heparin resulted in an improvement of endothelium-dependent vascular function, reflected by increases of brachial flow-mediated dilation and acetylcholine-induced forearm blood flow (42 ) .
MPO AND PLAQUE VULNERABILITY
Plaque destabilization and rupture are thought to be essential processes in inducing acute cardiovascular events. For example Rossi et al. found a higher incidence of unstable plaques in patients with AMI (20 ) . MPO may play a role in plaque destabilization by activating metalloproteinases, thereby weakening the fibrous cap. This notion is supported by several studies that showed a positive association of MPO and CVD mortality in patients with acute cardiovascular events, whereas 2 studies that included patients with stable CAD failed to show a predictive value of MPO for CVD (17, 19 MPO (45 ) . Consistent with this observation, these investigators found a higher concentration of proteins modified by hypochlorous acid in eroded and ruptured plaques compared to stable plaques. Taken together, existing data provide strong evidence that MPO may be involved in turning late-stage atherosclerosis into acute cardiovascular events.
Laboratory Analyses of MPO: Methodology and Pitfalls
Differences in study populations or analytical procedures may influence the estimated predictive value of MPO in CVD risk stratification. Most results from the above-mentioned studies are based on measurement of MPO mass. Although a high correlation between MPO mass and MPO activity (r ϭ 0.95) has been reported (15 ) , it cannot be completely ruled out that measurement of MPO activity instead of concentration would have influenced the results. As a matter of fact, the preferred assay procedure (mass or activity) is currently not known. It should be noted, however, that ex vivo measurement of MPO activity does not necessarily reflect the in vivo activity of the enzyme. Enzymatic activity of MPO strongly depends on the local concentration of the cosubstrate hydrogen peroxide, which is relatively high in the microenvironment of the subendothelial space, especially in individuals with risk factors associated with increased oxidative stress, such as smoking, hypertension, and type 2 diabetes. Laboratory measurement of MPO activity is usually performed in the presence of saturating amounts of substrate and hydrogen peroxide and therefore represents maximal enzyme activity that can most likely be regarded as a proxy for enzyme mass.
The type of analytical specimen also differs between studies; whole blood, leukocytes, and plasma have all been used. Additionally, measurement of MPO in plasma has been performed after an intravenous bolus injection of heparin, which mobilizes MPO from vascular compartments and therefore yields higher values compared to baseline plasma concentrations, especially in patients with CAD (42 ) . Heparin may induce MPO release in white blood cells (46 ) , and neutrophils are activated during coagulation of blood (47 ) . The effect of collection tubes on MPO concentrations has recently been studied in patients presenting with symptoms of ACS (48 ) . MPO concentrations were higher in serum and samples collected in heparin tubes than in samples collected in EDTA or citrate tubes. Moreover, samples collected into EDTA tubes stored on ice or at room temperature were the most stable. Plasma MPO concentrations remained relatively stable in heparin samples stored on ice, but storage at room temperature for 2 hours led to a 4-fold increase in MPO concentrations. From these results, Shih and coworkers concluded that EDTA should be the preferred anticoagulant for samples collected for MPO determination.
An additional issue that hampers comparison of reported MPO concentrations is the fact that some authors report MPO concentrations on a molar or weight basis, whereas others normalize to total protein by reporting MPO/protein ratios.
Clearly, reported measures of MPO are not directly comparable and are dependent on the type of specimen used. In fact, quite a few reports do not include information on the anticoagulant used to obtain plasma. Thus standardization of method protocols and blood collection tube type is urgently required.
Concluding Remarks
Epidemiological studies in a wide range of patient populations clearly indicate that MPO, in addition to traditional markers, is an important CVD risk marker, especially in patients with unstable CAD. The causative role of MPO in initiating CVD and acute cardiovascular events is supported by in vitro experiments and pathophysiological observations, indicating that MPO is involved in all stages of atherogenesis from endothelial dysfunction to plaque rupture. Before MPO can be used routinely in clinical practice for CVD risk stratification, however, a better understanding of and recommendations for preanalytical and analytical procedures are important.
